Current read
Early human evidence from 3 study records, 5 active source records, 4 rapid briefs, and 0 timeline events. Evidence maturity is 63/100, human translation signal is 71/100, and frontier activity is moderate (45/100). Frontier activity means research movement, not settled human proof. Editorial launch override: Proof of concept because Senescence is a foundational aging-biology lane, but current VV graph support is still mostly mechanism and adjacent inflammation evidence.
This lane has plausible intervention signals but is not mature human evidence.
Commercial bias penalty: 17/100. Confidence: 55/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Senolytics, senomorphics, and immune clearance strategies aimed at senescent-cell burden and inflammatory signaling. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 34/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
Senolytics, senomorphic drugs, immune-mediated clearance.
What would move this row up?
Current bottleneck
human translation, safety boundaries
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Evidence that would change the map
- Raise evidence maturity from 63/100 with better controlled studies or stronger replication.
- Raise human translation from 34/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not claim clearing senescent cells broadly reverses aging in humans.
- Do not treat animal lifespan signals as consumer-ready therapy.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
Sleep and Inflammation Review
Sleep and inflammation: partners in sickness and in health
Review from 2019 in Nature Reviews Immunology, translated into key findings, limitations, and consumer relevance.
Nature Reviews Immunology / 2019->
Linoleic Acid Inflammation Review
Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials
Systematic review from 2012 in Journal of the Academy of Nutrition and Dietetics, translated into key findings, limitations, and consumer relevance.
Journal of the Academy of Nutrition and Dietetics / 2012->
Guha cannabis aging brain
Lifetime Cannabis Use Is Associated with Brain Volume and Cognitive Function in Middle-Aged and Older Adults
Observational study from 2025 in Journal of Studies on Alcohol and Drugs, translated into key findings, limitations, and consumer relevance.
Journal of Studies on Alcohol and Drugs / 2025->
Useful source library entries
Related briefs
FDA Warns on Unapproved Cell and Tissue Products After Death Reports
FDA says unapproved human cell and tissue products marketed online may pose serious risks, including reports of patient deaths after use.
Why now
The gray-market regenerative medicine boom needs a clean evidence boundary alongside real cell and gene therapy breakthroughs.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 30, 2026
A First Patient Received Catheter-Delivered Lab-Grown Heart Cells
Heartseed's HS-005 program reportedly treated its first dilated cardiomyopathy patient with iPSC-derived cardiomyocyte spheroids delivered by catheter.
Why now
The original draft undersold this. The June cycle is not just a trade pickup. Heartseed announced first-patient dosing in a Phase I/II EMERALD study using catheter delivery of allogeneic iPSC-derived cardiomyocyte spheroids, with the first patient reportedly treated in late March and discharged after an uneventful early course. That makes the timing stronger: a first-in-human or first-in-world delivery-method milestone has moved from lab platform to patient dosing, while still having zero efficacy proof.
- Overclaim risk
- high
- Primary source
- Trade news
- Published
- Jun 28, 2026
The First Huntington's Patient Received Neural Stem Cells in a First-in-Human Trial
UCI Health treated the first patient in REGEN4HD, moving hNSC-01 from preclinical promise into human safety testing for Huntington's disease.
Why now
First-patient dosing moves a neural stem cell strategy for Huntington's disease from preclinical story to monitored human safety trial.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 27, 2026
An 18-Year-Old Burn Patient Received a World-First Exosome Treatment
Kaitlin Jeffrey reportedly avoided facial and neck skin grafting after experimental exosome injections, but this remains a single case, not established burn care.
Why now
A world-first patient story is drawing attention to exosomes as a possible regenerative tool in acute burn care.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 24, 2026
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
Does Cannabis Shrink Your Brain?
A viral claim turns cannabis brain research into a one-line shrinkage scare. The evidence is messier: blood flow, activation, volume, cognition, age, dose, and heavy-use patterns are not interchangeable.
VV Signal Score
58
Early or context-dependent
- Sources
- 10
- Studies
- 7
- Claims
- 7
Mold Toxicity: Real Indoor-Air Problem or Universal Symptom Funnel?
Mold exposure can matter for respiratory health, asthma, allergies, and vulnerable groups. That does not make every vague symptom proof of CIRS or a binder deficiency.
VV Signal Score
60
Early or context-dependent
- Sources
- 13
- Studies
- 13
- Claims
- 10
Seed Oils: Toxic Sludge or Internet Scapegoat?
Seed oils are blamed for inflammation, obesity, heart disease, and metabolic collapse. The stronger signal is not that linoleic-acid-rich oils are toxic. It is that they often travel inside ultra-processed food patterns.
VV Signal Score
55
Early or context-dependent
- Sources
- 7
- Studies
- 6
- Claims
- 10
Sleep Is More Than Hours—and Less Certain Than the Headlines
Poor sleep tracks with inflammation, chronic disease, and mortality risk. The signal is meaningful, but the strongest outcome evidence is observational—not proof that a better sleep score adds years to life.
VV Signal Score
65
Promising signal
- Sources
- 6
- Studies
- 6
- Claims
- 6
Claim ledger
Related claims
Claim ledger records matched by topic, intervention, study, or source links.
sleep: Sleep disturbance has biologically plausible links to inflammatory and
Sleep disturbance has biologically plausible links to inflammatory and immune dysregulation through cytokine, neuroendocrine, autonomic, and antiviral-response pathways, but inflammation mediation between sleep and mortality is not settled.
seed oils: Seed oils are not supported as toxic at normal
Seed oils are not supported as toxic at normal dietary exposure, though the food pattern they often appear in can still be low-quality.
seed oils: The blanket claim that seed oils cause inflammation is
The blanket claim that seed oils cause inflammation is not supported by human trial-review evidence on linoleic acid and inflammatory markers in healthy adults.
seed oils: Omega-6 fats are not inherently pro-inflammatory in the simple
Omega-6 fats are not inherently pro-inflammatory in the simple viral sense; mechanistic plausibility does not override human outcome and marker evidence.
seed oils: Canola oil being industrially processed is not by itself
Canola oil being industrially processed is not by itself a clinical harm endpoint.
seed oils: Seed-oil oxidation concerns are most plausible in repeated high-heat
Seed-oil oxidation concerns are most plausible in repeated high-heat frying and poor-storage contexts, not as a blanket indictment of ordinary culinary use.